---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035995"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2026-08-04T20:10:21+00:00"
generated_at: "2026-08-04T20:12:31.680534+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# RenovoRx to highlight TAMP platform at JonesTrading KOL webinar on Aug 13, 2026

## Summary
- RenovoRx to participate in JonesTrading KOL webinar on pancreatic cancer on Aug 13, 2026 at 1:30 p.m. ET.
- RenovoCath sales of ~$1.1M in 2025 and record $563K in Q1 2026.
- Full enrollment in Phase III TIGeR-PaC trial expected very near term; final data readout mid to late 2027.
- IAG (intra-arterial gemcitabine via RenovoCath) has Orphan Drug Designation for pancreatic and bile duct cancer.

## SEC filing metadata
- accession: 0001493152-26-035995
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2026-08-04T20:10:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/0001493152-26-035995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035995
- JSON: https://secwatch.observer/filing/0001493152-26-035995.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.